Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰 2023年度向特定对象发行A股股票募集资金使用的可行性分析报告（修订稿） | 2023-12-01 | Chinese | |
| 百奥泰 关于本次募集资金投向属于科技创新领域的说明（修订稿） | 2023-12-01 | Chinese | |
| 百奥泰 独立董事关于第二届董事会第十三次会议相关事项的专门会议意见 | 2023-12-01 | Chinese | |
| 百奥泰 2023年度向特定对象发行A股股票预案（修订稿） | 2023-12-01 | Chinese | |
| 百奥泰 关于5%以上股东权益变动的提示性公告 | 2023-12-01 | Chinese | |
| 百奥泰 第二届董事会第十三次会议决议公告 | 2023-12-01 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2023
15 filings
| |||||
| 39227844 | 百奥泰 2023年度向特定对象发行A股股票募集资金使用的可行性分析报告（修订稿） | 2023-12-01 | Chinese | ||
| 39227837 | 百奥泰 关于本次募集资金投向属于科技创新领域的说明（修订稿） | 2023-12-01 | Chinese | ||
| 39227825 | 百奥泰 独立董事关于第二届董事会第十三次会议相关事项的专门会议意见 | 2023-12-01 | Chinese | ||
| 39227813 | 百奥泰 2023年度向特定对象发行A股股票预案（修订稿） | 2023-12-01 | Chinese | ||
| 39227777 | 百奥泰 关于5%以上股东权益变动的提示性公告 | 2023-12-01 | Chinese | ||
| 39227758 | 百奥泰 第二届董事会第十三次会议决议公告 | 2023-12-01 | Chinese | ||
| 39227748 | 百奥泰 关于向特定对象发行A股股票摊薄即期回报与公司采取填补措施及相关主体承诺（修订稿）的公告 | 2023-12-01 | Chinese | ||
| 39227736 | 百奥泰 关于召开2023年第三季度业绩说明会的公告 | 2023-11-13 | Chinese | ||
| 39227721 | 百奥泰 2023年第三季度报告 | 2023-10-26 | Chinese | ||
| 39227705 | 上海市方达（广州）律师事务所关于百奥泰生物制药股份有限公司2023年第一次临时股东大会的法律意见书 | 2023-10-09 | Chinese | ||
| 39227694 | 百奥泰 2023年第一次临时股东大会决议公告 | 2023-10-09 | Chinese | ||
| 39227688 | 百奥泰 关于BAT1806（托珠单抗）注射液获得美国FDA上市批准的公告 | 2023-10-08 | Chinese | ||
| 39227680 | 百奥泰 2023年第一次临时股东大会会议资料 | 2023-09-21 | Chinese | ||
| 39227669 | 百奥泰生物制药股份有限公司 独立董事工作制度 | 2023-09-15 | Chinese | ||
| 39227662 | 百奥泰 与关联方签署分布式屋顶光伏电站能源管理协议暨关联交易的公告 | 2023-09-15 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.